[4-(3,5-Dimethylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone → (S)-[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl][4-(3-isopropyl-1,1-dioxo-1lambda6-isothiazolidin-2-yl)phenyl]methanone
반응식
[CH:1]([C@@H:4]1[CH2:8][CH2:7][S:6](=[O:10])(=[O:9])[NH:5]1)([CH3:3])[CH3:2].[CH3:11][C:12]1[C:13]([N:19]2[CH2:24][CH2:23][N:22]([C:25]([C:27]3[CH:32]=[CH:31][C:30](I)=[CH:29][CH:28]=3)=[O:26])[CH2:21][CH2:20]2)=[N:14][CH:15]=[C:16]([CH3:18])[CH:17]=1>>[CH3:11][C:12]1[C:13]([N:19]2[CH2:20][CH2:21][N:22]([C:25]([C:27]3[CH:32]=[CH:31][C:30]([N:5]4[C@H:4]([CH:1]([CH3:3])[CH3:2])[CH2:8][CH2:7][S:6]4(=[O:10])=[O:9])=[CH:29][CH:28]=3)=[O:26])[CH2:23][CH2:24]2)=[N:14][CH:15]=[C:16]([CH3:18])[CH:17]=1참가 물질
3
실험 절차
Using (S)-3-isopropylisothiazolidine 1,1-dioxide (300 mg) described in Preparation Example 6 and [4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone (421 mg) described in Preparation Example 113 and by the reaction and treatment in the same manner as in Example 4, the title compound (68 mg) was obtained.